About us
About us
Transforming transfusion diagnostics and beyond
We continually innovate to achieve new heights in diagnostics.

We are a commercial-stage diagnostics company that is fully committed to delivering solutions that reshape the way diagnostics is practiced.

Our fundamental objective is to empower our customers to realize their full potential and improve their business. Together, we are transforming transfusion diagnostics and beyond.

Originally established in Scotland in the 1940s as Alba Bioscience, Quotient’s then research and manufacturing subsidiary manufactured blood typing reagents as part of the Scottish National Blood Transfusion Service (SNBTS). In addition to supplying its products throughout the Scottish National Health System, Alba Bioscience expanded its operations and subsequently emerged as an original equipment manufacturer (OEM) supplier to the world’s leading transfusion diagnostics companies. In 2007, Alba Bioscience was privatized and became part of what is now known as Quotient.

Building on our strong heritage in transfusion diagnostics, in 2013, we introduced our proprietary multimodality multiplexing microarray technology, MosaiQ™, which represents the world’s first fully automated, consolidated testing platform. MosaiQ™ is a game-changing solution that was designed to increase efficiencies, improve clinical practice, deliver significant workflow improvements, and reduce operational costs within laboratories throughout the world.  In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient currently has offices in Eysins, Switzerland; Edinburgh, Scotland; and Newtown, Pennsylvania.

Management

Manuel O. Méndez, Chief Executive Officer

Manuel O. Méndez

Manuel O. Méndez joined Quotient (NASDAQ:QTNT)  as the company’s Chief Executive Officer in April 2021. 

He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts.  Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America.

An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University. 

Dr. Michael Hausmann, Chief Technology Officer

Dr. Michael Hausmann

Dr. Michael Hausmann joined Quotient (NASDAQ:QTNT) as the company’s Chief Technology Officer in August 2021. 

He has 24 years of experience in the in vitro diagnostics industry, including extensive R&D leadership experience at companies such as: Abbott, bioMérieux and most recently, Thermo Fisher Scientific.

He developed the ex-US Architect Infectious Disease portfolio for blood screening and diagnostics at Abbott; at bioMérieux, led the team to develop the VIDAS & VIDAS 3 assays. Most recently, at Thermo Fisher Scientific, he expanded the adoption of BRAHMS Procalcitonin in China and the US.

Dr. Hausmann holds a Ph.D. in Biology from the Max-Planck-Institute of Immunobiology and a MSc degree in Chemistry from Albert-Ludwigs-University in Freiburg, Germany. 

Peter Buhler, Chief Financial Officer

Peter Buhler

Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.

In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.

While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.

He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.

Jeremy Stackawitz, Chief Commercial Officer

Jeremy Stackawitz

Jeremy Stackawitz joined Quotient (NASDAQ:QTNT) in 2009, overseeing the company through a period of sustained rapid growth. He led Quotient’s entry into the US market, where the company now serves over 1,000 customers and has successfully obtained over 60 FDA product approvals. 

He brings over 20 years of experience in healthcare, including diagnostics, pharmaceuticals and biotechnology. His past experiences include serving in various business development, general management and commercial roles for Johnson & Johnson, which included Commercial Director of Immunohematology for Ortho Clinical Diagnostics.

Previously he worked at Purdue Pharma running various Market Research and Commercial groups, and served as a Strategy Consultant to the healthcare industry with Monitor and McKinsey & Co consultancies.

Mr Stackawitz holds a BA in Chemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.

Christian Albrich, Chief People Officer

Christian Albrich

Christian Albrich joined Quotient (NASDAQ:QTNT) as the company’s Chief People Officer in September 2021.

He brings 30 years of HR experience in the healthcare industry, designing effective and business-aligned people strategies, fostering high-performing cultures, and leading organizational development initiatives. Previously, he spent 20 years with Actelion Pharmaceuticals, now a JANSSEN Pharmaceutical company of Johnson & Johnson, where he served as the Senior Vice President and Head of Global Human Resources. Joining Actelion at the start-up phase, he transformed the HR function to support the rapid growth of the company. Prior to joining Actelion, Christian was Human Resources Director at Serono Pharmaceuticals in France and Belgium.

Careers

Quotient currently employs more than 400 expert professionals who are all working toward the same goal: To transform transfusion diagnostics and beyond. Joining Quotient represents a valuable opportunity to become part of a groundbreaking team that is set to re-shape the future and potential of diagnostics.
Careers
Media

Media

Read Quotient’s recent press releases, download our media kit, and discover the latest news about our industry and products.

Corporate Governance

The board of directors of Quotient Limited sets high standards for the company’s employees, officers and directors? Implicit in this philosophy is the importance of sound corporate governance.
Gender pay report 2020

Gender pay report

The gender pay gap shows the difference between the average earnings of men and women at Quotient.